These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
132 related articles for article (PubMed ID: 30532854)
1. Acquired long QT syndrome and ventricular tachycardia in a patient on flecainide therapy. Son CW; Lee SH; Shin DG; Hong GR; Park JS J Cardiol Cases; 2011 Jun; 3(3):e137-e142. PubMed ID: 30532854 [TBL] [Abstract][Full Text] [Related]
2. Flecainide induced ventricular tachycardia (torsades de pointes). Thevenin J; Da Costa A; Roche F; Romeyer C; Messier M; Isaaz K Pacing Clin Electrophysiol; 2003 Sep; 26(9):1907-8. PubMed ID: 12930510 [TBL] [Abstract][Full Text] [Related]
3. Flecainide-associated bradycardia-dependent torsade de pointes: another potential mechanism of proarrhythmia. Kim HS; Pak HN; Park JS; Kim SS Pacing Clin Electrophysiol; 2013 Mar; 36(3):e84-6. PubMed ID: 21029131 [TBL] [Abstract][Full Text] [Related]
4. Acquired prolongation of QT interval as a risk factor for torsade de pointes ventricular tachycardia: a narrative review for the anesthesiologist and intensivist. Uvelin A; Pejaković J; Mijatović V J Anesth; 2017 Jun; 31(3):413-423. PubMed ID: 28229241 [TBL] [Abstract][Full Text] [Related]
5. An unusual case of flecainide-induced QT prolongation leading to cardiac arrest. Oguayo KN; Oyetayo OO; Costa SM; Mixon TA Pharmacotherapy; 2014 May; 34(5):e30-3. PubMed ID: 24510469 [TBL] [Abstract][Full Text] [Related]
6. Torsades de pointes ventricular tachycardia induced by mosapride and flecainide in the presence of hypokalemia. Ohki R; Takahashi M; Mizuno O; Fujikawa H; Mitsuhashi T; Katsuki T; Ikeda U; Shimada K Pacing Clin Electrophysiol; 2001 Jan; 24(1):119-21. PubMed ID: 11227957 [TBL] [Abstract][Full Text] [Related]
7. Prevention of class III-induced proarrhythmias by flecainide in an animal model of the acquired long QT syndrome. Hallman K; Carlsson L Pharmacol Toxicol; 1995 Oct; 77(4):250-4. PubMed ID: 8577635 [TBL] [Abstract][Full Text] [Related]
8. Experimental models of torsades de pointes. Weissenburger J; Davy JM; Chézalviel F Fundam Clin Pharmacol; 1993; 7(1):29-38. PubMed ID: 8458600 [TBL] [Abstract][Full Text] [Related]
9. Torsades de pointes during laparoscopic adrenalectomy of a pheochromocytoma: a case report. van der Heide K; de Haes A; Wietasch GJ; Wiesfeld AC; Hendriks HG J Med Case Rep; 2011 Aug; 5():368. PubMed ID: 21838875 [TBL] [Abstract][Full Text] [Related]
10. [QT prolongation and torsade de pointes tachycardia during therapy with maprotiline. Differential diagnostic and therapeutic aspects]. Lentini S; Rao ML; Schröder R; Lüderitz B; Bauriedel G Dtsch Med Wochenschr; 2001 Dec; 126(49):1396-400. PubMed ID: 11740632 [TBL] [Abstract][Full Text] [Related]
11. Assessment of drug-induced proarrhythmia: The importance of study design in the rabbit left ventricular wedge model. Lu HR; Gallacher DJ; Yan GX J Pharmacol Toxicol Methods; 2016; 81():151-60. PubMed ID: 27374776 [TBL] [Abstract][Full Text] [Related]
12. Arrhythmogenic activities of antiarrhythmic drugs in conscious hypokalemic dogs with atrioventricular block: comparison between quinidine, lidocaine, flecainide, propranolol and sotalol. Weissenburger J; Davy JM; Chézalviel F; Ertzbischoff O; Poirier JM; Engel F; Lainée P; Penin E; Motté G; Cheymol G J Pharmacol Exp Ther; 1991 Nov; 259(2):871-83. PubMed ID: 1941633 [TBL] [Abstract][Full Text] [Related]
13. Torsade-de-pointes in a patient under flecainide treatment, an unusual case of proarrhythmicity. Nogales Asensio JM; Moreno Sánchez N; Doncel Vecino LJ; Villar Mariscal C; López-Mínguez JR; Merchán Herrera A Int J Cardiol; 2007 Jan; 114(2):E65-7. PubMed ID: 17056139 [TBL] [Abstract][Full Text] [Related]
14. [QT prolongation and induction of torsades de pointe by flecainide. Apropos of a case]. Wickers F; Haissaguere M; Palussiere J Arch Mal Coeur Vaiss; 1988 Oct; 81(10):1283-5. PubMed ID: 3146965 [TBL] [Abstract][Full Text] [Related]
16. A new biomarker--index of cardiac electrophysiological balance (iCEB)--plays an important role in drug-induced cardiac arrhythmias: beyond QT-prolongation and Torsades de Pointes (TdPs). Lu HR; Yan GX; Gallacher DJ J Pharmacol Toxicol Methods; 2013; 68(2):250-259. PubMed ID: 23337247 [TBL] [Abstract][Full Text] [Related]
17. Transient QT prolongation with torsades de pointes tachycardia after ablation of permanent junctional reciprocating tachycardia. Grimm W; Hoffmann J; Menz V; Maisch B J Cardiovasc Electrophysiol; 1999 Dec; 10(12):1631-5. PubMed ID: 10636193 [TBL] [Abstract][Full Text] [Related]
18. Determinants and mechanisms of flecainide-induced promotion of ventricular tachycardia in anesthetized dogs. Ranger S; Nattel S Circulation; 1995 Sep; 92(5):1300-11. PubMed ID: 7648679 [TBL] [Abstract][Full Text] [Related]
19. Pause-dependent torsade de pointes following acute myocardial infarction: a variant of the acquired long QT syndrome. Halkin A; Roth A; Lurie I; Fish R; Belhassen B; Viskin S J Am Coll Cardiol; 2001 Oct; 38(4):1168-74. PubMed ID: 11583899 [TBL] [Abstract][Full Text] [Related]
20. Moxifloxacin-induced QT prolongation and torsades: an uncommon effect of a common drug. Badshah A; Janjua M; Younas F; Halabi AR; Cotant JF Am J Med Sci; 2009 Aug; 338(2):164-6. PubMed ID: 19680025 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]